BGpartner advises Araris with Samsung Ventures investment

Samsung Ventures has made a strategic investment in Araris Biotech. The investment corporation, that was established to promote the development of new technologies, has invested in the company in an independent deal ahead of its on-going series A funding. The investment was made via Samsung Life Science Fund which reflects Samsung’s commitment to further explore and expand various business opportunities in biopharmaceuticals.

Araris Biotech, a company pioneering antibody-drug conjugate (ADC) linker technology, intends to use the proceeds to support further development and advancement of Araris’ antibody-drug conjugate (ADC) candidates.

BGPartner assisted Araris Biotech in the negotiations and advised on all Swiss legal matters regarding this strategic investment. The team was led by partner Oliver Gnehm (pictured left) and further consisted of Thomas Gysin (senior associate, pictured right).

mercedes.galan

SHARE